Century Therapeutics, LLC
3675 Market Street, Suite 200
About Century Therapeutics, LLC
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
25 articles with Century Therapeutics, LLC
Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates. Research and development update to be held on Thursday, December 16, 8:00-9:30 AM EST
Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update
Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that preclinical data from the Company’s CNTY-101 program and CAR-iT platform will be presented in two posters at the 63rd American Society of Hematology Annual Meeting & Exposition, on December 11-14, 2021 in Atlanta, Georgia and virtually.
Collaboration enables Century to explore Outpace’s protein solutions for cell therapy to enhance functionality of iPSC platform Initial program to focus on hematological malignancies with option to expand to additional candidates
Century Therapeutics announced that it will be added to the small-cap Russell 2000® Index as a part of the 3Q21 Russell Indexes IPO additions, effective at US market open on September 20, 2021, according to the preliminary list of IPO additions to the Russell indexes.
Century Therapeutics, (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the second quarter ended June 30, 2021.
Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Century Therapeutics today announced the closing of its initial public offering of 12,132,500 shares of its common stock at a public offering price of $20.00 per share, which includes the full exercise by the underwriters of their option to purchase 1,582,500 additional shares of common stock.
Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the pricing of its initial public offering of 10,550,000 shares of its common stock at a public offering price of $20.00 per share
Century Therapeutics , a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Alessandro Riva , M.D., and Kimberly Blackwell, M.D., as new Independent Directors.
5/7/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Pharmaceutical industry veteran Joe Jimenez appointed Board Chair Cynthia Butitta joins as Independent Director
3/10/2021Money flows into life sciences companies on a daily basis. Here’s who’s celebrating this week.
Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline
Financing led by Casdin Capital and joined by Fidelity Management & Research LLC, the Federated Hermes Kaufmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, Octagon Capital, and joined by founding investors Versant Ventures and Leaps by Bayer Capital to expand novel iPSC platform and drive product development
Century Therapeutics received a $160 million infusion of cash to advance the company’s pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.
Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey
Century Therapeutics announced a significant expansion of its operational and laboratory space in Philadelphia, as well as progress on its manufacturing facility in Branchburg, NJ, paving the way for a strong technical foundation as the company scales up its in-house research and development capabilities.
9/18/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Century Therapeutics , developer of induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer, today announced the appointment of Michael C. Diem, MD, as Chief Business Officer. Dr. Diem has more than 15 years of experience in the global pharmaceutical and biotech industries and nearly 10 years of experience in academic and clinical medicine. “I am excited to welcome Mike to Century as he shar
Century Therapeutics Canada will develop induced pluripotent Stem Cell (iPSC)-derived allogeneic immune cell therapies against glioblastoma (GBM)
Century Therapeutics, developer of induced pluripotent stem cell -derived allogeneic cell therapies for cancer, announced the formation of its Scientific Advisory Board to include several renowned experts in the fields of developmental and stem cell biology, genetics, and immuno-oncology.
New company site will focus on creating next-gen product candidates to break barriers in the treatment of solid tumors
1/31/2020Pharma and biotech companies strengthen their leadership teams and boards with this week's Movers & Shakers.